Form 4 for AVTR Avantor, Inc.
Accepted 2023-10-04 00:00:00 ET · period of report 2023-10-02 · accession 0001722482-23-000186 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2023-10-04 | 2023-10-02 | AVTR | Gourdier Benoit | EVP, Biopharma Production | A - Grant | $0.00 | +16.8K | 16.8K | New | $0 |
| D | 2023-10-04 | 2023-10-02 | AVTR | Gourdier Benoit | EVP, Biopharma Production | A - Grant | $0.00 | +39.3K | 39.3K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-10-02 | A | A | 16,786 | $0.00 | 16,786 | D | — | — | |
| 2 | Derivative | Stock Options (Right to Buy) | 2023-10-02 | A | A | 39,281 | $0.00 | 39,281 | D | $20.85 · — to 2033-10-02 | 39,281 Common Stock | (F2) Reflects a grant of stock options that vest in four equal annual installments beginning on October 2, 2024. |